Prospective evaluation of artemether-lumefantrine for the treatment of non-falciparum and mixed-species malaria in Gabon

Malaria Journal

Research

Benjamin Mordmüller¹  Peter G Kremsner¹  Daisy A Diop¹  Arti Basra¹  Fanny Joanny¹  Heike Würbel¹  Sabine Bélard²  Florian Kurth³  Christian Kleine⁴  Mesküre Capan⁵  Michael Ramharter⁵  Ayola A Adegnika⁶  Ghyslain Mombo-Ngoma⁷ 

[1] Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon;Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany;Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon;Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany;Centre for Paediatrics and Adolescent Medicine, University Medical Centre Freiburg, Freiburg, Germany;Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon;Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany;Department of Infectious Diseases and Pulmonary Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany;Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon;Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany;Department of Infectious Diseases, J.W. Goethe University Hospital, Frankfurt a. Main, Germany;Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon;Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany;Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria;Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon;Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany;Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands;Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon;Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany;Département de Parasitologie-Mycologie, Faculté de Médecine, Université des Sciences de la Santé, Libreville, Gabon;

关键词: Malaria;    Ovale;    Malariae;    Artemisinin-combination-therapy;    Artemether-lumefantrine;    Non-falciparum;   

DOI  :  10.1186/1475-2875-11-120

 received in 2012-02-16, accepted in 2012-04-19,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundThe recommendation of artemisinin combination therapy (ACT) as first-line treatment for uncomplicated falciparum malaria is supported by a plethora of high quality clinical trials. However, their recommendation for the treatment of mixed-species malaria and the large-scale use for the treatment of non-falciparum malaria in endemic regions is based on anecdotal rather than systematic clinical evidence.MethodsThis study prospectively observed the efficacy of artemether-lumefantrine for the treatment of uncomplicated non-falciparum or mixed-species malaria in two routine district hospitals in the Central African country of Gabon.ResultsForty patients suffering from uncomplicated Plasmodium malariae, Plasmodium ovale or mixed-species malaria (including Plasmodium falciparum) presenting at the hospital received artemether-lumefantrine treatment and were followed up. All evaluable patients (n = 38) showed an adequate clinical and parasitological response on Day 28 after oral treatment with artemether-lumefantrine (95% confidence interval: 0.91,1). All adverse events were of mild to moderate intensity and completely resolved by the end of study.ConclusionsThis first systematic assessment of artemether-lumefantrine treatment for P. malariae, P. ovale and mixed-species malaria demonstrated a high cure rate of 100% and a favourable tolerability profile, and thus lends support to the practice of treating non-falciparum or mixed-species malaria, or all cases of malaria without definite species differentiation, with artemether-lumefantrine in Gabon.Trial RegistrationClinicalTrials.gov Identifier: NCT00725777

【 授权许可】

Unknown   
© Mombo-Ngoma et al.; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.